Eric Green, MD, Ph.D., promoted to Scientific Director
SOUTH SAN FRANCISCO, Calif., October 13, 2022–(BUSINESS WIRE)–Maze Therapeutics, a company that translates genetic insights into new precision medicines, today announced the appointment of Harold Bernstein, MD, Ph.D., a longtime industry veteran 30 years, in the position of president, director of research and development (R&D) and chief medical officer. Additionally, Eric Green, MD, Ph.D., who served as Maze’s Senior Vice President, Research and Translational Sciences, has been promoted to Chief Scientific Officer.
“Harold brings an impressive combination of industry and academic experience, as well as the unique perspective of a medical practitioner, to the Maze team at an important stage in our development. Additionally, with much of the experience of Harold’s focus on human genetics, he is a natural fit for this position, and I am thrilled to welcome him to our team and our mission,” said Jason Coloma, Ph.D., Maze’s Chief Executive Officer. also pleased to announce the promotion of Eric to CSO, who has been a true leader and driving force behind much of the advancement of Maze’s platform and pipeline since our founding. Eric and Harold will be instrumental in executing the advancement of our diverse pipeline, which spans monogenic diseases like Pompe disease and more complex diseases like chronic kidney disease. I look forward to partnering with these two experts as we realize our vision of harnessing the power of human genetics to transform the lives of patients.
“Maze has attracted some of the best minds in biotechnology and has proven itself with impressive progress since its inception, including the development of its Compass platform and its rapid advancement into the clinic,” said Dr. Bernstein. “I was drawn to the noble goal of the Maze team to change the paradigm of medicine, especially for more complex diseases such as chronic kidney disease, at a time unprecedented for the field of genetics and precision medicine. As Head of R&D, I look forward to shaping and contributing to a creative strategy and deep scientific process to deliver new gene-based medicines. I am excited to join the Maze team as we work urgently to create and advance therapeutically meaningful treatments to help patients in need.
Dr. Bernstein brings over three decades of experience in basic science research, translational medicine, and clinical development, in both industry and academia. He joins Maze from BioMarin, where he served as senior vice president, chief medical officer and head of global clinical development. In this role, he was responsible for strengthening early-stage to late-stage clinical development, working seamlessly with research discovery, and overseeing late-stage and lifecycle products. Prior to BioMarin, he was Head of Translational Medicine and Vice President of Global Drug Development and Medical Affairs at Vertex, and previously held positions at Merck including Head of Early Development for Cardiometabolic Diseases. Dr. Bernstein was a professor of pediatrics and a principal investigator at the Cardiovascular Research Institute and the Broad Center of Regeneration Medicine and Stem Cell Research at the University of California, San Francisco (UCSF). He was also an attending physician at UCSF Benioff Children’s Hospital in Pediatric Cardiology and at Mount Sinai Kravis Children’s Hospital in Cardiovascular Genetics. Dr. Bernstein currently serves as Assistant Professor of Pediatrics and the Mindich Institute of Child Health and Development at the Icahn School of Medicine at Mount Sinai. He studied Biomedical Sciences, Human Genetics, and Medicine at Mount Sinai School of Medicine, earning a Masters of Philosophy, Ph.D. and MD He completed a Pediatrics Residency, Cardiology Fellowship, and Postdoctoral Fellowship at UCSF and earned an AB in Biological Sciences from Harvard College.
Dr. Green is a physician-scientist and entrepreneur with over 15 years of experience building and operating innovative science organizations. Prior to Maze, Dr. Green was an entrepreneur-in-residence at Third Rock Ventures, where he was involved in launching and building several Third Rock portfolio companies, including MyoKardia where he led the translational research group working on the mavacamten, which was eventually acquired. by Bristol Myers Squibb. Dr. Green is a board-certified physician with training in internal medicine and cardiovascular medicine from Brigham and Women’s Hospital. He holds an MD and a Ph.D. in Chemistry and Systems Biology from Stanford University and an AB in History and Science from Harvard College.
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company that applies advanced data science methods in tandem with a robust suite of research and development capabilities to advance a pipeline of novel precision medicines for patients with genetically defined diseases. Maze developed the Maze CompassMT platform, a proprietary, purpose-built platform that combines human genetic data, functional genomics tools, and data science technology to map novel connections between known genes and their influence on susceptibility, timing of onset, and the rate of disease progression. Using Compass, Maze is building a broad portfolio of wholly owned and partnered programs. Maze is based in South San Francisco. For more information, visit mazetx.com or follow us on LinkedIn and Twitter.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20221013005211/en/
Jillian Connell, Maze Therapeutics
Katie Engleman, 1AB
#Maze #Therapeutics #Appoints #Harold #Bernstein #Ph.D #President #Research #Development #Chief #Medical #Officer